Important Information
If you are interested in applying for this study, please:
- read the study description.
- review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Description
New Zealand Clinical Research is trialling an investigational medicine that could help people with asthma.
The medicine, HB0056, may help people with asthma by reducing the body’s immune and inflammation response. This is designed to help reduce the symptoms that are experienced by patients.
This is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
Clinical trials involve an investigative drug and some study assessments. Clinical trials are managed under the care of our experienced research team.
This study (2024 FULL 21162) is being funded by Shanghai Huaota Biopharmaceutical Co. and has been approved by the Health and Disability Ethics Committee.
Requirements
Healthy Males and Females
- Aged between 18 – 55 years
- BMI (Body Mass Index) between 18 kg/m2 – 32 kg/m2
- Smokers/Vapers (less than 5 per day) allowed
- Not currently taking any regular prescription medications (e.g., anti-depressants)
What is Involved?
Study Visits: 4-night stay + 11 clinic visits
Reimbursement: Up to $5,000 before tax